TABLE 1

Cox Proportional Hazards Analysis of Factors Influencing Appearance of IAs and tTGAs, Their Order of Appearance, and Co-occurrence of IA and tTGA

ModelCharacteristicsIAstTGAsCo-occurrence IAs and tTGAs
HR (95% CI)PHR (95% CI)PHR (95% CI)P
UnadjustedtTGA preceding IA1.01 (0.69–1.50).95
IA preceding tTGA1.30 (1.01–1.67).04
AdjustedtTGA preceding IA1.12 (0.75–1.67).57
IA preceding tTGA1.48 (1.15–1.91).0027
CountryUS111
FIN1.56 (1.21–2.00).0006*1.24 (1.03–1.50).0271.60 (0.89–2.90).12
GER1.14 (0.76–1.71).531.19 (0.87–1.64).280.96 (0.36–2.56).94
SWE1.31 (1.04–1.65).023*1.57 (1.34–1.84)<.00011.58 (0.95–2.62).08
HLA-DR-DQDR 4/4 or 4/8111
DR 3/30.69 (0.50–0.96).028*5.32 (4.32–6.56)<.00011.88 (0.97–3.64).06
DR 3/41.47 (1.18–1.82).005*2.05 (1.68–2.51)<.00011.94 (1.12–3.35).018*
SexMale111
Female0.76 (0.63–0.92).0039*1.61 (1.41–1.84)<.00011.19 (0.78–1.80).42
T1D FDRNo111
Yes2.60 (2.03–3.33)<.0001*1.07 (0.84–1.34).602.69 (1.54–4.67).0005*
Celiac FDRNo111
Yes1.01 (0.59–1.73).972.02 (1.53–2.66)<.00010.58 (0.14–2.37).45
RGS1 (rs2816316)1.10 (0.94–1.30).250.87 (0.77–0.99).0290.87 (0.59–1.30).50
CTLA4 (rs3087243)0.99 (0.87–1.14).940.82 (0.74–0.90)<.00010.88 (0.65–1.19).42
CCR3 (rs6441961)1.04 (0.91–1.20).571.06 (0.96–1.17).291.20 (0.88–1.63).25
SH2B3 (rs3184504)1.30 (1.14–1.49)<.0001*1.06 (0.97–1.17).211.53 (1.14–2.05).005*
PTPN2 (rs45450798)0.96 (0.80–1.14).610.99(0.87–1.12).831.10 (0.76–1.60).60
HLA-DPB1*04:011.17 (0.94–1.47).160.86 (0.74–1.02).080.72 (0.45–1.16).18
HLA-DPB1*04:020.81 (0.60–1.11).190.93 (0.76–1.15).520.57 (0.28–1.15).12
HLA-DPB1*01:011.03 (0.77–1.37).851.12 (0.94–1.34).210.89 (0.51–1.55).67
HLA-DPB1*02:011.21 (0.93–1.57).170.90 (0.73–1.10).290.91 (0.52–1.60).75
HLA-DPB1*03:011.28 (0.98–1.68).081.08 (0.88–1.31).480.85 (0.47–1.54).59
  • Factors analyzed include country, sex, FH of T1D or CD, and HLA-DR-DQ, HLA-DPB1, and 5 non-HLA antigen genetic loci. FIN, Finland; GER, Germany; SWE, Sweden; US, United States; —, not applicable.

  • * P < .05